The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

CONTEXT: The Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) extension is evaluating the long-term efficacy and safety of denosumab for up to 10 years. OBJECTIVE: The objective of the study was to report results from the first 3 years of the extension, representin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bone, Henry G., Chapurlat, Roland, Brandi, Maria-Luisa, Brown, Jacques P., Czerwiński, Edward, Krieg, Marc-Antoine, Mellström, Dan, Radominski, Sebastião C., Reginster, Jean-Yves, Resch, Heinrich, Ivorra, Jose A. Román, Roux, Christian, Vittinghoff, Eric, Daizadeh, Nadia S., Wang, Andrea, Bradley, Michelle N., Franchimont, Nathalie, Geller, Michelle L., Wagman, Rachel B., Cummings, Steven R., Papapoulos, Socrates
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2013
Materias:
Endocrine Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207950/
https://www.ncbi.nlm.nih.gov/pubmed/23979955
http://dx.doi.org/10.1210/jc.2013-1597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207950/
https://www.ncbi.nlm.nih.gov/pubmed/23979955
http://dx.doi.org/10.1210/jc.2013-1597

Ejemplares similares